Patient Case Studies
These case studies are reflective of many typical situations when a determination and diagnosis of RLS is reached:
MIRAPEX has no predicted P450 interactions an important consideration in patients on multiple medications.
MIRAPEX has no predicted P450 interactions an important consideration in patients on multiple medications. Contraindications
Learn more about dosing and administration of MIRAPEX
Learn more about dosing and administration of MIRAPEXLearn more about dosing and administration of MIRAPEX
Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).
Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for RLS, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (16% vs. 5%), headache (16% vs. 15%), fatigue (9% vs. 7%) and somnolence (6% vs. 3%).
Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.
This information is intended for U.S. residents only. Products discussed herein may have different labeling in different countries.
Please see full Prescribing Information, including patient information.
